Trial Profile
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies; Seizures
- Focus Registrational; Therapeutic Use
- Sponsors BIAL - Portela C S.A.
- 22 Jun 2021 Results assessing long-term efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for adults with focal seizures presented at the 7th Congress of the European Academy of Neurology
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.
- 22 Apr 2021 Results assessing 10 years of post-marketing surveillance (PMS) safety data of eslicarbazepine acetate collected from randomised clinical trials in adults: BIA-2093-201, -301, -302 -303, -304 and -311, presented at the 73rd Annual Meeting of the American Academy of Neurology.